Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Mizuho Discusses Biogen (BIIB) Seizure Patient
December 9, 2016 2:15 PM ESTMizuho analyst Salim Syed discussed Biogen (NASDAQ: BIIB) Aducanumab's LTE seizure patient, which has the stock well off highs (+0.4%).
"On the seizure patient, we spoke to the company (they weren't willing to say much beyond the slide) ... this is a new... More
Biogen (BIIB) Shares Should Trade Higher on CTAD Data - BMO Capital
December 9, 2016 6:29 AM ESTBMO Capital analyst M. Ian Somaiya expects shares of Biogen (NASDAQ: BIIB) to trade higher CTAD data, which show: 1) solanezumab caused small yet consistent improvements on secondary endpoints, including CDR-SB (aducanumab's P3 endpoint); and (2) aducanumab titration yielded efficacy similar to 6-10mg/kg... More
UPDATE: Biogen (BIIB), Biotechs Gain Mid-Day
December 8, 2016 3:03 PM EST(Updated - December 8, 2016 3:07 PM EST)
Biogen (NASDAQ: BIIB), other biotechs gain mid-day. May be related to conference commentary.
UPDATE: The upside is said related to aducanumab data, which was released from embargo earlier. Adam Feuerstein tweeted:
... More
